10-K: Fennec Pharmaceuticals Reports Record 2025 PEDMARK Sales, Eliminates Debt

Fennec Pharmaceuticals announced record net product sales of $44.6 million for fiscal year 2025, a 50% increase year-over-year, alongside the full redemption of its outstanding debt.

Summary

• Fennec Pharmaceuticals Inc. is a commercial-stage specialty pharmaceutical company focused on preventing cisplatin-induced ototoxicity (CIO) with its FDA and European Commission approved product, PEDMARK/PEDMARQSI.
• Net product sales for fiscal year 2025 reached $44.6 million, a 50% increase from $29.6 million in fiscal year 2024.
• Total revenue for fiscal year 2025 was $44.6 million, a decrease from $47.5 million in 2024, primarily due to the absence of a $17.9 million licensing revenue from the Norgine transaction in 2024.
• The company reported a net loss of $9.7 million for fiscal year 2025, compared to a net loss of $0.4 million in 2024, influenced by the absence of 2024 licensing revenue and a $2.0 million loss on debt extinguishment.
• Cash and cash equivalents increased to $36.8 million as of December 31, 2025, from $26.6 million at December 31, 2024, driven by equity offerings and product sales.
• All outstanding senior secured convertible notes, totaling approximately $21.7 million, were redeemed in November 2025, resulting in $0 debt outstanding at year-end.
• PEDMARQSI was launched in Germany and the U.K. in 2025 through the partnership with Norgine, with additional European launches expected in 2026 and beyond.
• Positive topline results were announced in December 2025 from the STS-J01 investigator-initiated clinical trial in Japan, evaluating PEDMARK for CIO prevention in pediatric and AYA patients, showing significant hearing loss reduction without compromising antitumor activity.
• The company is pursuing a regulatory registration strategy for PEDMARK in Japan and evaluating partnering opportunities in that market.
• Fennec HEARS, a patient support program, expanded its capabilities in 2025, offering financial and product access support.
• The Cipla ANDA litigation regarding a generic version of PEDMARK was settled on March 16, 2026, with Cipla agreeing not to enter the market until September 1, 2033, or earlier under certain circumstances.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this filing positively due to robust product sales growth, successful international expansion, positive clinical data, and the significant strengthening of the balance sheet through debt elimination, positioning the company for sustained future growth despite the reported net loss.

Positives

• Record annual net product sales of $44.6 million in FY2025, representing 50% year-over-year growth.
• Fourth quarter 2025 net product sales grew 75% over Q4 2024, reaching $13.8 million.
• Successful full redemption of all outstanding senior secured convertible notes in November 2025, eliminating debt.
• Cash and cash equivalents increased to $36.8 million by December 31, 2025, from $26.6 million in 2024.
• Positive topline results from the STS-J01 investigator-initiated clinical trial in Japan, demonstrating PEDMARK's efficacy in reducing hearing loss without compromising cisplatin's antitumor activity.
• PEDMARQSI launched commercially in Germany and the U.K. in 2025 through the Norgine licensing agreement, with further European launches anticipated.
• Settlement of the Cipla ANDA litigation, securing market exclusivity for PEDMARK until September 1, 2033, or earlier under specific conditions.
• Expansion of commercial infrastructure and patient support programs (Fennec HEARS) in 2025, leading to increased market penetration and formulary adoption.
• NCCN recommended PEDMARK for Adolescent and Young Adult (AYA) Oncology (category 2A) for localized, non-metastatic solid tumors.
• Six patents listed for PEDMARK in the FDA Orange Book, expiring in 2039, providing long-term intellectual property protection.

Negatives

• Reported a net loss of $9.7 million for fiscal year 2025, a significant increase from $0.4 million in 2024.
• Total revenue decreased in 2025 compared to 2024, primarily due to the absence of a $17.9 million licensing revenue from the Norgine transaction in the prior year.
• General and administrative expenses increased by $5.2 million in fiscal 2025, driven by higher consulting, professional fees, and equity remuneration.
• Interest income decreased by $0.9 million in fiscal 2025 due to lower average invested cash balances and lower yields.
• The company has a history of significant losses and has generated limited revenue from product sales since its inception, making future profitability uncertain.
• PEDMARK is currently the company's only product, making it highly dependent on its commercial success and vulnerable to any disruptions.

Risks

• Dependence on a single product (PEDMARK) for all foreseeable product revenues, making the business vulnerable to any adverse developments.
• Potential need for additional financing to obtain further regulatory approvals and commercialize PEDMARK abroad, with no assurance of obtaining capital on acceptable terms.
• Substantial competition from major pharmaceutical and biotechnology companies with greater resources, and from compounded sodium thiosulfate which is less expensive.
• Reliance on third-party manufacturers and suppliers, exposing the company to risks of production delays, quality issues, and increased costs.
• Uncertainty in obtaining foreign regulatory approvals, which are lengthy, expensive, and unpredictable, potentially delaying or preventing international commercialization.
• Ongoing regulatory review and compliance requirements for PEDMARK, with potential for sanctions, product recalls, or withdrawal if regulations are not met.
• Risk of product liability claims from clinical testing, manufacture, and sale of PEDMARK, with insurance coverage potentially being inadequate.
• Market acceptance and sales of PEDMARK depend on coverage and adequate reimbursement from third-party payors, which may be limited or unavailable.
• The target patient population for PEDMARK is small, requiring significant market share and high per-patient prices to achieve meaningful gross margins, which could be challenged by cheaper alternatives.
• Intellectual property rights may be challenged, narrowed, invalidated, or circumvented by competitors, despite current patent protection and the Cipla settlement.
• Cybersecurity threats and incidents could compromise information technology systems or data, leading to regulatory investigations, litigation, financial losses, and reputational harm.
• Geopolitical instability and armed conflicts in regions like Turkey and the Middle East could disrupt product distribution and sales.

Future Outlook

Fennec Pharmaceuticals anticipates continued growth in PEDMARK adoption across key accounts and patient segments, including the Adolescent and Young Adult (AYA) population. The company expects additional launches of PEDMARQSI in European countries in 2026 and beyond. A regulatory registration strategy for PEDMARK in Japan is being pursued, with evaluation of partnering or licensing opportunities. The company also supports investigator-initiated studies to expand the clinical evidence base for PEDMARK in additional tumor types and adult populations, though label expansion will require further clinical data and regulatory approvals. Management believes current capital resources are sufficient for at least the next 12 months, but anticipates incurring further losses as it continues development and seeks international marketing approvals.

Management Comments

• "Our 2025 results validate that our strategy is clear and the foundation we built over the past year is now propelling Fennec into its next chapter of growth. We delivered record net product sales, achieved significant growth within our Fennec HEARS program, and advanced independent clinical evidence generation for PEDMARK — all while driving quarter-over-quarter growth in every quarter in 2025." Jeff Hackman, Chief Executive Officer.
• "These results demonstrate increasing PEDMARK adoption across key accounts and patient segments, effective field execution, and sustained progress across the organization, demonstrating that the Company’s growth strategies are well aligned with market opportunities." Jeff Hackman, Chief Executive Officer.
• "Concurrently, we strengthened our financial position through prudent operating decisions and strategic financial initiatives, including the closing of public and private offerings and the completion of full debt redemption." Jeff Hackman, Chief Executive Officer.

Industry Context

StockSavvy.ai notes that Fennec Pharmaceuticals operates in the highly competitive and regulated biotechnology and pharmaceutical industry, specifically targeting the niche market of cisplatin-induced ototoxicity (CIO) prevention in pediatric and AYA cancer patients. The company's focus on an orphan drug indication provides certain market exclusivity benefits, which are crucial given the small patient population. The successful commercialization of PEDMARK in the U.S. and its expansion into Europe through a partnership with Norgine, a leading European specialist pharmaceutical company, aligns with a common industry strategy for smaller biopharmaceutical firms to leverage established partners for international market access. The positive results from the investigator-initiated trial in Japan further validate the product's potential and open new geographic opportunities, reflecting a trend towards global market expansion for specialized therapies. The ongoing challenges of securing reimbursement and competing with compounded alternatives are typical for novel, high-cost orphan drugs, requiring robust patient access programs like Fennec HEARS.

Comparison to Industry Standards

• PEDMARK is the first and only FDA-approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin in pediatric patients, setting a new standard of care in this specific unmet medical need.
• In clinical studies (COG ACCL0431 and SIOPEL 6), PEDMARK demonstrated an approximate 50% relative reduction in cisplatin-induced hearing loss compared to cisplatin alone, without materially compromising antitumor efficacy, which is a strong clinical outcome for a preventative therapy.
• The NCCN's Category 2A recommendation for PEDMARK in Adolescent and Young Adult (AYA) Oncology for localized, non-metastatic solid tumors indicates strong clinical endorsement, comparable to other established therapies in oncology guidelines.
• The settlement with Cipla, preventing generic entry until September 1, 2033, provides a significant period of market exclusivity, which is a critical competitive advantage for an orphan drug, often sought through extensive patent litigation in the pharmaceutical industry.
• The upfront consideration of approximately $43 million and potential for up to $230 million in milestones and double-digit tiered royalties from the Norgine licensing agreement for Europe, Australia, and New Zealand is a substantial deal for a single-product company, reflecting strong partner confidence in PEDMARQSI's market potential, comparable to successful licensing agreements for other specialized therapies.

Management Changes

Corporate Governance

Legal Proceedings

• The company was involved in ANDA litigation against CIPLA Ltd. and CIPLA USA (CIPLA) concerning their application for a generic version of PEDMARK, alleging infringement of several Fennec patents (US 190, US 728, US 984, US 793, US 018, US 530, US 604, US 026 Patents).
• The litigation was settled on March 16, 2026, with the lawsuit dismissed and each party bearing its own costs.
• Under the settlement terms, Cipla will not enter the market with its generic sodium thiosulfate product until September 1, 2033, or earlier under certain specified circumstances.

Stakeholder Impact

• Shareholders: Positive impact due to strong product sales growth, successful international expansion, and the elimination of all outstanding debt, which strengthens the company's financial position. The settlement of the Cipla litigation also provides clarity and extended market exclusivity.
• Patients: Positive impact as PEDMARK/PEDMARQSI becomes more widely available in the U.S., Europe, and potentially Japan, offering a crucial therapy to reduce cisplatin-induced ototoxicity in pediatric and AYA cancer patients. Patient support programs like Fennec HEARS enhance access.
• Employees: Positive impact from the company's growth and expansion, including an expanded commercial team and competitive compensation/benefits programs designed to attract and retain talent.
• Partners (Norgine, Inpharmus): Continued collaboration and potential for milestone payments and royalties based on commercialization success in licensed territories.
• Creditors: Positive impact from the full repayment of all outstanding debt, demonstrating strong financial management and reducing credit risk.

Next Steps

• Norgine expects additional launches of PEDMARQSI in other European countries in 2026 and beyond.
• Pursuing a regulatory registration strategy for PEDMARK in Japan.
• Evaluating partnering or licensing opportunities for PEDMARK in the Japanese market.
• Supporting investigator-initiated clinical studies to further characterize PEDMARK's use in additional tumor types and patient populations, including AYA and adult populations.
• Continuing medical affairs activities and data-generation initiatives to expand the clinical evidence base for PEDMARK.
• Monitoring and upgrading internal controls as necessary or appropriate for the business.
• Evaluating the impact of ASU 2024-03 (Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures) on consolidated financial statements, effective for annual periods beginning after December 15, 2026.
• Evaluating the impact of ASU 2025-05 (Measurement of Credit Losses for Accounts Receivable and Contract Assets) on consolidated financial statements, effective for annual fiscal years beginning after December 15, 2025.

Key Dates

Recommendation

The filing presents a compelling case for a 'buy' recommendation. Fennec Pharmaceuticals demonstrated significant commercial momentum with a 50% year-over-year increase in net product sales for PEDMARK, its sole commercial product. The successful international expansion through the Norgine partnership and positive clinical data from Japan indicate strong global growth potential. Crucially, the company eliminated all outstanding debt, significantly de-risking its balance sheet and improving its financial flexibility. While a net loss was reported, it was influenced by the absence of prior-year licensing revenue and a one-time debt extinguishment loss, rather than a deterioration in core commercial performance. The settlement of the Cipla litigation provides extended market exclusivity, securing future revenue streams. These factors collectively point to a company with strong operational execution and a clear path to increased shareholder value.

Keywords

PEDMARK, sodium thiosulfate, cisplatin-induced ototoxicity, CIO, pediatric cancer, oncology, hearing loss prevention, biopharmaceutical, orphan drug, SEC filing, 10-K, financial results, drug approval, Norgine, Japan clinical trial, patent litigation, commercialization